Open Beta
TREN
MetriLume
TREN

US marketsPYXS

SEC-sourced researchBeta

PYXS

Pyxis Oncology, Inc.

Company comparison ↗

Data passport

CIK
0001782223
Exchange
Nasdaq
Business activity
— · SIC 2834
Financial inputs
6/6
Filing date
Oct 5, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 16,146,000.0000 USD; December 2025: 13,858,000.0000 USD16.1M USD0 USD0December 2024December 2025
PYXS · Exact amounts and source periods · USD
Period endRevenueFiling date
December 202416,146,000.0000Mar 23, 2026
December 202513,858,000.0000Mar 23, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 202513,858,000.0000-79,621,000.0000-63,502,000.000091,520,000.000038,112,000.0000Mar 23, 2026
December 202416,146,000.0000-77,331,000.0000-57,672,000.0000157,181,000.000036,430,000.0000Mar 23, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenues$13.86MDecember 2025Mar 23, 202610-K
Previous period revenueRevenues$16.15MDecember 2024Mar 23, 202610-K
Net incomeNetIncomeLoss-$79.62MDecember 2025Mar 23, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$63.5MDecember 2025Mar 23, 202610-K
Total assetsAssets$91.52MDecember 2025Mar 23, 202610-K
Total liabilitiesLiabilities$38.11MDecember 2025Mar 23, 202610-K

New filings

Explore methodology ↗